Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
NCT00914732
Completed
Due to recent concern of biowarfare and bioterrorism, the US government is making efforts to improve its ability to protect citizens against the smallpox virus. This study will evaluate safety of IMVAMUNE®, an investigational smallpox vaccine, and its ability to stimulate the immune system (the body's defense system). Two vaccine preparations have the same name but one is a liquid and one is a powder that has liquid added just before it is given. The vaccine that comes as a liquid will be inject... Read More
Gender:
ALL
Ages:
Between 18 years and 38 years
Trial Updated:
01/13/2021
Locations: Emory Vaccine Center - The Hope Clinic, Decatur, Georgia +7 locations
Conditions: Smallpox
Register for Updates
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
NCT02721043
Completed
The purpose of this study is to test the safety, tolerability, and immunogenicity of Personalized Genomic Vaccine 001 (PGV001) in subjects with advanced non-hematologic malignancies. PGV001 is a peptide vaccine that is based on a patient's own tumor sequence. Each patient's tumor is sequenced and peptides that correspond to the tumors are made. These peptides combined with the adjuvant Poly-ICLC (Hiltonol®, Oncovir) make PGV001. The adjuvant Poly-ICLC is added to boost the immune response to the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2021
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Solid Tumors
Register for Updates
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
NCT02184572
Completed
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/15/2020
Locations: GSK Investigational Site, Birmingham, Alabama +94 locations
Conditions: Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Register for Updates
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
NCT01681992
Completed
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/15/2020
Locations: GSK Investigational Site, Birmingham, Alabama +80 locations
Conditions: Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Register for Updates
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
NCT01101750
Completed
The purpose of the study is to understand if children with liver and kidney transplants develop the antibodies from the Gardasil vaccine. The Gardasil vaccine protects against Human Papilloma Virus (HPV) types 16 and 18, which cause most types of cancers of the cervix, vagina and vulva. It also protects against Human Papilloma Virus types 6 and 11, which cause genital warts in some people. Gardasil has been approved by the Food and Drug Administration and is recommended for girls and women from... Read More
Gender:
ALL
Ages:
Between 9 years and 17 years
Trial Updated:
12/14/2020
Locations: Georgetown University Hospital, Washington, District of Columbia +1 locations
Conditions: Cervical Cancer, Hpv, Warts
Register for Updates
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
NCT02388165
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +301 locations
Conditions: Staphylococcal Vaccine
Register for Updates
This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
NCT03207750
Completed
The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age
Gender:
ALL
Ages:
Between 6 weeks and 12 weeks
Trial Updated:
12/07/2020
Locations: GSK Investigational Site, Birmingham, Alabama +46 locations
Conditions: Rotavirus Infection, Rotavirus Vaccines
Register for Updates
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
NCT00970203
Completed
This study will evaluate the feasibility, safety, and efficacy of intradermal vaccination of prostate cancer patients with alpha-type-1-polarized dendritic cells (DC1) loaded with apoptotic allogeneic tumor (LNCap). The study will target men with recurrent prostate cancer, who failed local therapy, have no measurable metastasis, but have a rising PSA with a doubling time of less than 10 months. The selection of this study group enables us to evaluate time to PSA progression, a highly relevant, c... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/13/2020
Locations: University of Pittsburgh Cancer institute, Pittsburgh, Pennsylvania
Conditions: Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms, Prostatic Cancer
Register for Updates
Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults
NCT04227210
Completed
This study evaluates an investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV). The investigational vaccine (MV-012-968) is administered as drops in the nose. This study specifically analyzes the safety of, and the immune response to, the vaccine when administered to healthy non-pregnant adults between the ages of 18 and 40 years.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
09/13/2020
Locations: Johnson County Clin-Trials, Lenexa, Kansas
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
NCT04540185
Unknown
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2020
Locations: Coronavirus Research Institute- Testing Site, Los Angeles, California +9 locations
Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Register for Updates
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
NCT03384316
Completed
Background: ETBX-011, ETBX-061, and ETBX-051 are cancer vaccines. Their goal is to teach the immune system to target and kill cancer cells. The vaccines target 3 proteins found in many types of cancer. Researchers think targeting all 3 proteins in unison will have the best results. Objective: To test the safety of combining ETBX-011, ETBX-061, and ETBX-051 and their effects on the immune system. Eligibility: People ages 18 and older with advanced cancer that has not responded to standard th... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/25/2020
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Prostate Cancer, Lung Cancer, Breast Cancer, Colon Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01266460
Completed
This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/21/2020
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +23 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
Register for Updates